Why Partner

There are 3 key challenges gene therapy developers are struggling to address:

Translatability of Neurological Preclinical Models

  • Rodent disease models for neurological disorders
  • Non-human primate (NHP) models for toxicity profiling and dosage extrapolation
  • Large animal models for improved disease recapitulation

Delivery to the CNS

  • Next generation vectors for CNS cell specificity and selectivity
  • Drug delivery technology to revolutionize administration routes to the brain

Neurodegenerative Biomarkers & Outcome Measures

  • Digital biomarkers and wearable technology to transform clinical trials
  • Neurological imaging advances
  • Blood-based biomarker innovations

As the opportunity in gene therapy rapidly expands, the 3rd Annual Gene Therapy for Neurological Disorders Europe meeting is your opportunity to demonstrate your expertise and elevate your brand in front of both established and emerging gene therapy developers, as they seek commercial partners for their expanding pipelines.

We are looking for
Companies Attending

Audience Breakdown

graph 1

To find out more how to elevate your brand, form meaningful relationships with KOLs, and capture new business with emerging companies in the CNS field, don’t hesitate to get in touch with us to find out more about how we can build a bespoke package to suit your 2022 business needs.